Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.77 |
| ▸ | TK1 | P04183 | 2/20 | 0.58 |
| ▸ | TK2 | O00142 | 2/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.52 |
| ▸ | CDA | P32320 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fialuridine SCHEMBL1533997 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL3084377 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL30674 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL13702050 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL3084382 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL9059414 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL24359134 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL773510 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL20769829 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL12658448 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2403863-B1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | PYGM 3116/4885TK1 143/4885TK2 190/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | PYGM 3144/4885TK1 155/4885TK2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.